BeOne Medicines Gains FDA Priority Review for TEVIMBRA in First-Line HER2+ Gastroesophageal Adenocarcinoma
BeOne Medicines Ltd., a global oncology-focused biopharmaceutical company, has announced a major regulatory milestone in the development of a promising new treatment approach for patients with advanced HER2-positive gastroesophageal adenocarcinoma (GEA). The U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) when used in combination with ZIIHERA® (zanidatamab) and chemotherapy as a first-line treatment option for patients with unresectable locally advanced or metastatic HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma.
This designation reflects the FDA’s recognition of the potential clinical significance of the regimen, particularly in a disease area where treatment advancements have historically been limited. In addition to Priority Review status, the FDA has also granted Breakthrough Therapy Designation to the ZIIHERA-based combination regimen, administered alongside fluoropyrimidine- and platinum-containing chemotherapy, both with and without TEVIMBRA. This dual regulatory recognition underscores the therapy’s potential to offer substantial improvements over existing standard-of-care treatments.
The regulatory submissions are supported by compelling clinical data from the global Phase 3 HERIZON-GEA-01 trial, which evaluated the safety and efficacy of ZIIHERA in combination with chemotherapy, with and without TEVIMBRA, compared with the current standard regimen of trastuzumab plus chemotherapy. The results of this study suggest that the addition of TEVIMBRA to the treatment regimen may significantly improve patient outcomes, particularly in terms of overall survival (OS).
One of the most notable findings from the HERIZON-GEA-01 trial was the statistically significant improvement in median overall survival observed in patients receiving the TEVIMBRA-containing combination. The study reported a median OS of 26.4 months in the TEVIMBRA plus ZIIHERA and chemotherapy arm, representing an unprecedented survival outcome in this difficult-to-treat patient population. By comparison, patients receiving ZIIHERA plus chemotherapy without TEVIMBRA achieved a median OS of 24.4 months, while those in the control arm treated with trastuzumab plus chemotherapy had a median OS of 19.2 months.
These results are particularly meaningful given the historically poor prognosis associated with advanced HER2-positive GEA. For more than a decade, survival outcomes in this disease setting have seen only modest improvements, highlighting the urgent need for more effective first-line treatment options.
In addition to improvements in overall survival, the HERIZON-GEA-01 study also demonstrated significant gains in progression-free survival (PFS). Both treatment arms that included ZIIHERA achieved a median PFS of 12.4 months, compared to 8.1 months in the control group. This indicates that the investigational combinations not only extend patients’ lives but also delay disease progression more effectively than current standard therapies.
Importantly, the clinical benefits observed in the trial were consistent regardless of PD-L1 expression status, suggesting that the therapy may be broadly applicable across a wide range of patients with HER2-positive disease. This is a key advantage, as PD-L1 status can often limit the effectiveness or eligibility for certain immunotherapy-based treatments.
From a safety perspective, the combination of TEVIMBRA, ZIIHERA, and chemotherapy demonstrated a tolerability profile that was consistent with the known safety characteristics of each individual component. No new or unexpected safety signals were identified during the study, providing reassurance that the regimen can be administered without introducing additional significant risks to patients.
According to Dr. Mark Lanasa, Chief Medical Officer for Solid Tumors at BeOne Medicines, the results of the HERIZON-GEA-01 trial have the potential to reshape the current treatment paradigm for HER2-positive gastroesophageal adenocarcinoma. He emphasized that achieving a median survival exceeding two years represents a major breakthrough in a disease that has long been associated with poor outcomes and limited therapeutic progress. Dr. Lanasa also noted that the FDA’s Priority Review designation marks an important step toward making this new treatment option available to patients as quickly as possible.
BeOne Medicines has indicated its intention to further accelerate the global development and availability of this regimen through participation in the FDA’s Project Orbis initiative. Project Orbis is designed to facilitate concurrent regulatory review of oncology products across multiple international health authorities, enabling faster access to innovative cancer therapies worldwide. Through this collaborative framework, the company aims to submit the HERIZON-GEA-01 data to regulatory agencies in multiple regions where it holds commercialization rights for ZIIHERA.
The HERIZON-GEA-01 trial itself is a large-scale, randomized, open-label Phase 3 study conducted in collaboration with Jazz Pharmaceuticals. The trial enrolled a total of 914 patients across approximately 300 clinical sites in more than 30 countries, reflecting a diverse and globally representative patient population. Participants included adults with unresectable locally advanced, recurrent, or metastatic HER2-positive gastroesophageal adenocarcinoma, defined by specific HER2 expression criteria based on immunohistochemistry (IHC) and in situ hybridization (ISH) testing.
Patients in the trial were randomized into three treatment groups: one receiving ZIIHERA in combination with chemotherapy and TEVIMBRA; another receiving ZIIHERA plus chemotherapy without TEVIMBRA; and a control group receiving trastuzumab plus chemotherapy. The study’s dual primary endpoints were progression-free survival, as assessed by blinded independent central review, and overall survival.
Gastroesophageal adenocarcinoma remains a major global health challenge. It is among the most common cancers worldwide, ranking as the fifth most frequently diagnosed malignancy. The disease encompasses cancers of the stomach, gastroesophageal junction, and esophagus. Approximately 20% of patients with GEA have tumors that overexpress the HER2 protein, a biomarker associated with aggressive disease and poorer clinical outcomes.
Despite advances in cancer research and treatment, the prognosis for patients with GEA remains relatively poor. The global five-year survival rate for gastric cancer is less than 30%, and for gastroesophageal adenocarcinoma overall, it is estimated to be around 19%. These statistics highlight the critical need for more effective therapies, particularly in the first-line setting where early intervention can have the greatest impact on long-term outcomes.
The promising results from the HERIZON-GEA-01 trial suggest that combining targeted HER2 therapy with immunotherapy and chemotherapy may represent a new standard of care for patients with HER2-positive GEA. By simultaneously targeting multiple pathways involved in tumor growth and immune evasion, this combination approach has the potential to deliver more durable and meaningful responses.
As the FDA completes its review of the sBLA under the Priority Review timeline, the oncology community will be closely watching for a potential approval decision. If approved, the TEVIMBRA, ZIIHERA, and chemotherapy combination could become a transformative new option for patients facing this challenging disease, offering improved survival and renewed hope where it is urgently needed.
About BeOne
BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before
